MIOCONSULT provides expert IFRS advisory services to biotech and pharmaceutical companies, specialising in revenue recognition (IFRS 15) for licensing deals and business combinations.

Our Expertise:

* Revenue recognition for biotech and pharmaceutical licensing transactions
* IFRS 15 implementation and compliance for complex deals
* Advisory on milestone payments, royalties, and variable consideration 
* In-licensing deal accounting covering asset classification (IAS 38),                business combinations (IFRS 3), joint arrangements (IFRS 11), and investment accounting (IAS 27/28)
* Equity transfer accounting in alliance deals from a consolidation perspective
* Business combination accounting guidance
* Training and workshops for finance teams

Industry Focus:

Biotechnology, pharmaceuticals, and medical technology companies requiring specialist accounting guidance for licensing arrangements, alliance deals, complex revenue streams, and equity-linked transactions.

Founded by Michelle Olufeso Nwokobia: Former Head of Accounting & External Relations at Roche and co-developer of IFRS 15 through the IASB/FASB process, bringing over 12 years of hands-on experience with €10M+ licensing deals and complex alliance structures.

Contact: info@mioconsult.com | +49 1522 6001338

MIOCONSULT

Org chart

Teams

Offices